Answers are grounded in this paper and cite their sources.
Lung ischemia and reperfusion (LIR) injury can lead to systemic and neurological complications, potentially exacerbating Alzheimer's disease (AD). Riociguat (RIO) has shown promise in reducing ischemia-reperfusion injuries. LIR-induced neuroinflammation in brain tissue contributes to beta amyloid (Aβ) accumulation. This study hypothesizes that RIO could mitigate AD progression by reducing brain damage, neuroinflammation, and Aβ accumulation secondary to LIR. Forty Wistar Albino male rats were randomly divided into 4 groups: sham, LIR, LIR+RIO, and RIO. LIR was induced using a vascular clamp on the hilus for 60 minutes, followed by 60 minutes of reperfusion. RIO was administered 30 minutes before ischemia. Brain tissues were analyzed histopathologically and immunohistochemically. Histopathology revealed marked hyperemia, degenerative changes, neuronal loss, gliosis, and inflammatory cell infiltrations in the LIR group. Immunohistochemical analysis showed increased Aβ, Cas-3, and TNF-α levels. RIO treatment effectively reversed these changes, indicating its potential in reducing brain damage, neuroinflammation, and Aβ accumulation. The results suggest that brain changes following lung ischemia-reperfusion in a rat model may predispose to Alzheimer's disease, but RIO may be effective in preventing this condition.
No takes yet. Share an insight, caveat, or question.
Özmen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: